Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B).
Sim SH, Kim JE, Kim MH, Park YH, Kim JH, Suh KJ, Koh SJ, Park KH, Kang MJ, Ahn MS, Lee KE, Kim HJ, Ahn HK, Kim HJ, Park KU, Byun JH, Park JH, Lee GW, Lee KS, Sohn J, Jung KH, Park IH.
Sim SH, et al. Among authors: park yh, park ih, park jh, park kh, park ku.
Breast. 2022 Oct;65:172-178. doi: 10.1016/j.breast.2022.08.002. Epub 2022 Aug 17.
Breast. 2022.
PMID: 36029565
Free PMC article.
Clinical Trial.